Research
Name | Type | Target | Compound Name | Phase |
---|---|---|---|---|
Tiziana Life Sciences
Direct delivery of anti-IL6 Mabs to the lungs |
New Therapies (Antibody-based) | IL-6 receptor (CD126) | TZLS-501 | Pre-Clinical |
Roche
Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia |
New Therapies (Antibody-based) | IL-6 receptor (CD126) | Actemra tocilizumab (RoActemra) | Phase III |
Collaboration: Regeneron / Sanofi
An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19 |
New Therapies (Antibody-based) | IL-6 receptor (CD126) | Kevzara sarilumab | Phase II / III |
Chongqing Sidemu Biotechnology Technology
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19 |
New Therapies (Protein-based) | IL15 superagonist; GM-CSF-neutralizing scFv | Natural killer (NK) cell therapy | Phase I / II |
CTK Biotech
RT-PCR and IgM/IgG test kits now available |
Research (Testing Kits) | IgG/IgM | N/A | Pre-Clinical |
Stanford University
New assay to detect presence of IgM and IgG against SARS-CoV-2 virus with peripheral blood (i.e. fingersticks) |
Research (Testing Kits) | IgM and IgG antibodies | N/A | Pre-Clinical |
Chongqing Medical University
Antibody responses to SARS-CoV-2 in patients with COVID-19 |
Research (Antibody Response) | IgM and IgG antibodies | N/A | Phase II |
Zydus Cadila
Zydus explores the biologicals route to treat novel Coronaviruswith long-acting Interferon alpha-2b |
New Therapies (Small Molecule) | Interferon (IFN) alpha receptor | PegiHep pegylated interferon alpha-2b | Pre-Clinical |
Swedish Orphan Biovitrum
A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection. |
New Therapies (Antibody-based) | Interferon gamma | Gamifant emapalumab | Phase II / III |
Swedish Orphan Biovitrum
A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection. |
New Therapies (Protein-based) | Interleukin-1 (IL-1) receptor 1 (IL1R1) | Kineret anakinra | Phase II / III |
Noxopharm
Idronoxil inhibits a key inflammatory pathway involved in a process known as a cytokine storm, which is associated with an abnormally excessive inflammatory response and is believed to be responsible for most deaths in patients with COVID-19 infection |
New Therapies (Protein-based) | Interleukin-6 (IL-6) | Oral idronoxil (NOX-19) | Pre-Clinical |
Collaboration: Incyte / Novartis
Phase 3 RUXCOVID Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm |
New Therapies (Small Molecule) | Janus kinase-1 (JAK-1); JAK-2 | Jakavi ruxolitinib | Phase III |
Erasme University Hospital
Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (ATCO) |
New Therapies (Peptide) | MAS receptor | Angiotensin-(1-7) | Phase II / III |
MediciNova
MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS) |
New Therapies (Small Molecule) | MIF; PDE-4; PDE-10 | Ibudilast | IND |
NYU Winthrop Hospital
In seven patients (four female), regardless of anticoagulation status, all autopsies demonstrated platelet-rich thrombi in the pulmonary, hepatic, renal, and cardiac microvasculature. Megakaryocytes were seen in higher than usual numbers in the lungs and heart. |
Research (Epidemiology) | Megakaryocytes | N/A | Research |
Bonus Biogroup
MesenCure was developed for the treatment of acute and life-threatening respiratory distress in coronavirus (COVID-19) and pneumonia patients. MesenCure consists of activated Mesenchymal Stromal Cells (“MSCs”) that are isolated from the adipose tissue of healthy donors. |
New Therapies (Cell-based) | Mesenchymal Stromal cells | MesenCure | Pre-Clinical |
Collaboration: Tonix Pharmaceuticals & Southern Research
Replicating Viral Vector currenly in preclinical testing |
Vaccine (Viral Vector) | Multiple antigens | TNX-1800 | Pre-Clinical |
University of California, Davis; National Primate Research Center
Non-human primate model of COVID-19 infection to explore therapies, vaccines and effect of age |
Research (Non-Human) | N/A | N/A | Pre-Clinical |
University of California, San Franscico
UCSF Researchers Aim to Enroll One Million Individuals for Real-Time Epidemiology |
Research (Epidemiology) | N/A | N/A | Pre-Clinical |
UCSF, Quantitative Bioscience Institute
Reseach of how SARS-CoV-2 hijacks human cells for its own replication |
Research (Epidemiology) | N/A | N/A | Pre-Clinical |
La Jolla Institute of Immunology
To develop prophylactic/therapeutic antibody preparations |
New Therapies (Antibody-based) | N/A | N/A | Pre-Clinical |
Colorado State University
Testing and Analysis of SARS-CoV-2 protective gear |
Research (Personal Protection) | N/A | N/A | Pre-Clinical |
Purdue University
Development of diagnostic tools for SARS-CoV-2 |
Research (Testing Kits) | N/A | N/A | Pre-Clinical |
University of Iowa/ Stanley Pearlman Lab
Exploring inflammation in murine model of SARS-CoV-2 infection and vaccine development |
Research (Non-Human) | N/A | N/A | Pre-Clinical |
Johns Hopkins University
Genomic sequencing of SARS-CoV-2 |
Research (Epidemiology) | N/A | N/A | Pre-Clinical |